Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cellular RNA adenosines susceptible to low-level TadA-8e-mediated deamination refers to the collection of adenosine residues within the transcriptome that undergo unintended adenosine-to-inosine (A-to-I) conversion by the TadA-8e enzyme. TadA-8e is a highly active, laboratory-evolved variant of the Escherichia coli tRNA adenosine deaminase (TadA) used in CRISPR-based Adenine Base Editors (ABEs) to convert A•T base pairs to G•C in DNA (Richter et al., 2020, Nature Biotechnology). While TadA-8e significantly improves DNA editing efficiency, its high affinity for nucleic acids results in widespread, guide-independent RNA editing (Lapinaite et al., 2020, Science). These off-target RNA modifications can lead to the production of mutant proteins, altered RNA stability, or disrupted splicing patterns, posing potential safety risks for therapeutic applications (Grünewald et al., 2019, Nature). Because these edits occur across the transcriptome rather than at a single therapeutic locus, they are characterized as a systemic off-target effect rather than a traditional drug target. Researchers have developed refined variants, such as TadA-8e-V106W, to mitigate these transcriptome-wide effects while preserving high-efficiency DNA editing (Kim et al., 2019, Nature Biotechnology). Monitoring these susceptible RNA sites is a critical component of the safety assessment for any ABE-based gene therapy.
Hydrolytic deamination of adenosine to inosine in RNA molecules, catalyzed by the TadA-8e enzyme component of a base editor.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cellular RNA adenosines susceptible to TadA-8e-mediated deamination (TadA-8e RNA off-targets).